⚠ Evidence warning: Clinical trials or other evidence do not support the traditional and marketed use of Chanca Piedra to lower blood sugar in people with diabetes. This page keeps it as a report of what people, websites or other media say.

Chanca Piedra for Blood Sugar

Blood Sugar — scientific infographic poster

Chanca Piedra is sometimes promoted as a "natural metformin." It is not. The plant has documented glucose-lowering effects in cell culture and rodent models, and two small, short human studies have given mixed results. The human evidence is thin, and compounds from other plants (berberine in particular) have substantially stronger glycemic-control evidence. This page covers the actual mechanisms, the real effect sizes, where Chanca Piedra fits, and where the marketing oversells it.


Table of Contents

  1. Mechanisms (Mostly Preclinical)
  2. Animal Data — Streptozotocin (STZ) and Alloxan Diabetic Rats
  3. Human Trials
  4. Comparative Strength vs Other Glycemic Herbs
  5. Lipids, Weight, and Metabolic Syndrome
  6. Practical Use Case
  7. Drug Interactions in Diabetics
  8. Dosing
  9. Realistic Expectations
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Mechanisms (Mostly Preclinical)

Four mechanisms have been proposed; the first, third and fourth have some support in test-tube or rodent studies:

The mechanisms are mechanistically plausible. The translation to human clinical effect is what's uncertain.

Back to Table of Contents

Animal Data — Streptozotocin (STZ) and Alloxan Diabetic Rats

Streptozotocin-induced diabetic rats are the standard preclinical model. Results from the Phyllanthus literature:

Two named rat studies give the detail. In rats made diabetic with alloxan (a chemical that destroys insulin-making cells), a methanol extract of Phyllanthus niruri aerial parts lowered blood sugar, blunted the rise after a glucose meal, reduced hemoglobin glycation, raised liver weight and liver glycogen, and lessened the weight loss caused by the diabetes (Okoli 2011). In alloxan-diabetic rats, a methanol extract of Phyllanthus amarus lowered blood sugar 4 hours after a dose by 6% at 200 mg/kg and by 18.7% at 1,000 mg/kg; after 15 days of daily dosing the reduction was significant, and by day 18 the 1,000 mg/kg group’s values were almost normal (Raphael 2002).

These are clean preclinical results. The translation factor — rat-mg/kg to human equivalent dose — usually shrinks effect size substantially when extrapolated to clinical practice.

Back to Table of Contents

Human Trials

The clinical literature is dominated by kidney stones and hepatitis B; diabetes-specific human trials are scarce. What exists:

The human signal is mixed and not robustly supported: one uncontrolled 10-day report saw blood glucose fall, one 1-week study saw no fall. No human study found has measured hemoglobin A1c in people taking Chanca Piedra.

Back to Table of Contents

Comparative Strength vs Other Glycemic Herbs

Strongest to weakest evidence for glycemic control among the major herbal options:

  1. Berberine — multiple randomized controlled trials (RCTs), hemoglobin A1c reduction 0.7–1.0%, comparable to metformin in some head-to-head studies. The strongest herbal glycemic agent by a clear margin.
  2. Gymnema sylvestre — moderate randomized controlled trial (RCT) data, hemoglobin A1c reduction 0.5–0.8%
  3. Fenugreek — moderate, hemoglobin A1c reduction 0.3–0.9%, dose-dependent (5–10 g/day)
  4. Cinnamon (cassia) — weak/inconsistent, hemoglobin A1c reduction 0.0–0.3%, meta-analyses split
  5. Bitter melon — weak, hemoglobin A1c reduction 0.1–0.4%, gastrointestinal (GI) side effects common
  6. Chanca Piedra — weakest of the group for diabetes specifically. Promising preclinical, sparse clinical.

Of the herbs above, berberine has the most randomized-trial evidence for glucose control; in one 3-month pilot trial in 36 adults with newly diagnosed type 2 diabetes, its glucose-lowering effect was similar to metformin’s (Yin 2008). Chanca Piedra has its strengths elsewhere (kidney stones, liver) but is not a leading diabetes intervention.

Back to Table of Contents

Lipids, Weight, and Metabolic Syndrome

Two placebo-controlled trials in people with fatty liver measured blood fats:

Chanca Piedra is not a metabolic-syndrome treatment in any meaningful clinical sense. In these two trials, blood-fat changes did not differ from placebo, apart from total cholesterol in one dose group of the combination product.

Back to Table of Contents

Practical Use Case

How the evidence above bears on common situations for people with metabolic concerns:

Uses the evidence does not support:

Back to Table of Contents

Drug Interactions in Diabetics

Back to Table of Contents

Dosing

Amounts and schedules commonly listed for blood-sugar use (no blood-sugar trial has tested them):

Back to Table of Contents

Realistic Expectations

Back to Table of Contents

Key Research Papers

  1. Raphael KR, Sabu MC, Kuttan R (2002). Hypoglycemic effect of methanol extract of Phyllanthus amarus Schum & Thonn on alloxan induced diabetes mellitus in rats and its relation with antioxidant potential. Indian J Exp Biol. 40(8):905-9. — PubMed PMID: 12597020
  2. Okoli CO, Obidike IC, Ezike AC, Akah PA, Salawu OA (2011). Studies on the possible mechanisms of antidiabetic activity of extract of aerial parts of Phyllanthus niruri. Pharm Biol. 49(3):248-55. — PubMed PMID: 21323477
  3. Srividya N, Periwal S (1995). Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus. Indian J Exp Biol. 33(11):861-4. — PubMed PMID: 8786163
  4. Moshi MJ, Lutale JJ, Rimoy GH, Abbas ZG, Josiah RM, Swai AB (2001). The effect of Phyllanthus amarus aqueous extract on blood glucose in non-insulin dependent diabetic patients. Phytother Res. 15(7):577-80. — PubMed PMID: 11746836
  5. Yin J, Xing H, Ye J (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 57(5):712-7. — PubMed PMID: 18442638
  6. Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL (2013). Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial. J Gastroenterol Hepatol. 28(1):57-62. — PubMed PMID: 23034128
  7. Shaker MK, Hassany M, Eysa B, Adel A, Zidan A, Mohamed S (2025). The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. BMC Complement Med Ther. 25(1):8. — PubMed PMID: 39789561

PubMed Topic Searches

  1. PubMed: Phyllanthus & diabetes
  2. PubMed: Hypoglycemic activity
  3. PubMed: STZ rat model
  4. PubMed: Phyllanthin & AMPK
  5. PubMed: Corilagin alpha-glucosidase
  6. PubMed: Berberine vs metformin

Back to Table of Contents

Connections

Back to Table of Contents